Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma

Kinase inhibitors represent the backbone of targeted cancer therapy, yet only a limited number of oncogenic drivers are directly druggable. By interrogating the activity of 1,505 kinase inhibitors, we found that BRD4-NUT-rearranged NUT midline carcinoma (NMC) cells are specifically killed by CDK9 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Brägelmann, Johannes, Dammert, Marcel A., Dietlein, Felix, Heuckmann, Johannes M., Choidas, Axel, Böhm, Stefanie, Richters, André, Basu, Debjit, Tischler, Verena, Lorenz, Carina, Habenberger, Peter, Fang, Zhizhou, Ortiz-Cuaran, Sandra, Leenders, Frauke, Eickhoff, Jan, Koch, Uwe, Getlik, Matthäus, Termathe, Martin, Sallouh, Muhammad, Greff, Zoltán, Varga, Zoltán, Balke-Want, Hyatt, French, Christopher A., Peifer, Martin, Reinhardt, H. Christian, Örfi, László, Kéri, György, Ansén, Sascha, Heukamp, Lukas C., Büttner, Reinhard, Rauh, Daniel, Klebl, Bert M., Thomas, Roman K., Sos, Martin L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622049/
https://www.ncbi.nlm.nih.gov/pubmed/28930680
http://dx.doi.org/10.1016/j.celrep.2017.08.082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622049/
https://www.ncbi.nlm.nih.gov/pubmed/28930680
http://dx.doi.org/10.1016/j.celrep.2017.08.082

Ejemplares similares